Revusiran. The Phase 3 ENDEAVOR study evaluated the investigational RNA interference therapeutic revusiran, that targets hepatic TTR production, for the treatment of CA caused by hereditary transthyretin-mediated amyloidosis, Patients with CA were randomized 2:1 to receive subcutaneous daily revusiran 500 mg (n = 140) or placebo (n = 66) for 5 days over a week followed by weekly doses. Here, TTR is linked to amyloidosis.